Rilapladib 是 Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) 的选择性抑制剂 (IC50 = 230 pM) 和血小板活化因子受体的拮抗剂。

Rilapladib is a selective inhibitor of Lipoprotein-Associated Phospholipase A2(Lp-PLA2, IC50 = 230 pM) and an antagonist of the platelet activating factor receptor.

Rilapladib reduces the PAF biological activity and levels, thereby reducing Lp-PLA2 biosynthesis and preventing the possible adverse effects of Lp-PLA2 [2].

412950-08-4

C40H38F5N3O3S

735.81

SB 659032

DMSO:78mg/mL (106mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years